News coverage about Cellectar Biosciences (NASDAQ:CLRB) has been trending positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellectar Biosciences earned a coverage optimism score of 0.28 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.7094745233411 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of equities analysts have issued reports on CLRB shares. Zacks Investment Research upgraded Cellectar Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. ValuEngine upgraded Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
Shares of Cellectar Biosciences (CLRB) traded up 0.882% during trading on Friday, reaching $1.715. The company’s stock had a trading volume of 200,709 shares. The firm’s market capitalization is $23.88 million. Cellectar Biosciences has a 52 week low of $1.12 and a 52 week high of $3.07. The company has a 50 day moving average price of $1.69 and a 200 day moving average price of $1.76.
Cellectar Biosciences (NASDAQ:CLRB) last announced its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. On average, equities research analysts expect that Cellectar Biosciences will post ($0.92) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/10/08/cellectar-biosciences-clrb-receives-news-impact-score-of-0-28.html.
About Cellectar Biosciences
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.